Prostate cancer (PCa) is the most commonly diagnosed cancer and the second leading cause of cancer-related death in men[1]. Androgen deprivation therapy (ADT) is the primary systemic treatment strategy for PCa[2]. ADT improves the survival of PCa patients but may also exert cardiotoxic effects. Many studies suggest that PCa patients who receive ADT have a higher risk of major adverse cardiovascular events (MACE)[3,4]. Cardiovascular disease is the most common noncancer cause of death in PCa pati…